Drug profile · INN
pegcetacoplan
EMPAVELI
pegcetacoplan (EMPAVELI) is a complement c3 inhibitor. Associated with Swedish Orphan Biovitrum Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — pegcetacoplan
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- SUBCUTANEOUS
- Patents
- 12
- Programs
- 17
- Data quality
- 0.89
Quick answer
pegcetacoplan (EMPAVELI) is a complement c3 inhibitor. Associated with Swedish Orphan Biovitrum Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Complement C3 inhibitor
Primary target: Complement C3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
-
US 12290566
Dosing regimens and related compositions and methods
granted -
US 12251395
RNAS for complement inhibition
granted -
US 11903994
Dosing regimens
granted -
US 11844841
Dosing regimens and related compositions and methods
granted -
US 11661441
Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
granted -
US 11510939
RNAs for complement inhibition
granted -
US 11291407
Detection of high risk drusen
granted -
US 11292815
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
granted -
US 11040107
Dosing regimens and related compositions and methods
granted -
US 10875893
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
granted -
US 10125171
Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
granted -
US 10035822
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
granted
Frequently asked questions
What is pegcetacoplan?
pegcetacoplan (EMPAVELI) is a complement c3 inhibitor. Associated with Swedish Orphan Biovitrum Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for pegcetacoplan?
EMPAVELI is a marketed brand name for pegcetacoplan. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pegcetacoplan?
pegcetacoplan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.